Severe cognitive impairment

Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress

Friday, October 15, 2021 - 7:00pm

53 LR

Key Points: 
  • 53 LR
    Cash and cash equivalents of CHF8.0 million (as of June30, 2021)
    Net revenue CHF4.5 million (H1-2020: CHF7.8 million)
    Net result for period of CHF-20.5 million (H1-2020: CHF-31.8 million)
    Pratteln, Switzerland, October15, 2021 Santhera Pharmaceuticals (SIX: SANN) announces the Companys financial results for the first half-year ended June30, 2021, and provides an update on corporate progress.
  • Already in April 2021, Santhera and ReveraGen announced new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD).
  • Based on clinical trial results, including long-term safety data up to 30 months, vamorolone at doses up to 6mg/kg/day was generally well-tolerated.
  • In June 2021, Santhera announced positive topline results from its long-term Phase 4 LEROS study with Raxone (idebenone) in the treatment of LHON.

Benetech Receives Support from Lavelle Fund for the Blind to Bridge Education to Employment Gap in India

Thursday, October 14, 2021 - 4:00pm

The program, supported by the Lavelle Fund for the Blind, will help launch the digital transformation of 10 schools for the blind across India.

Key Points: 
  • The program, supported by the Lavelle Fund for the Blind, will help launch the digital transformation of 10 schools for the blind across India.
  • Most schools for the blind and visually impaired in India rely on braille textbooks for education, said Dr. Homiyar Mobedji, Bookshare Asia and Africa Program Manager.
  • India has an estimated 62 million blind and visually impaired residents, the highest population in the world.
  • The Lavelle Fund primarily concentrates its giving in the areas of Medical Eye Care, Vision Rehabilitation & Resources, and Education.

Helping Hand for Relief and Development Marks World Sight Day With Its End of The Year Prevention of Blindness Campaign

Thursday, October 14, 2021 - 3:32pm

SOUTHFIELD, Mich., Oct. 14, 2021 /PRNewswire/ -- Helping Hand for Relief and Development (HHRD) observes this year's World Sight Day theme of Love Your Eyes with a nationwide Prevention of Blindness campaign advocating for cataract awareness and surgery.

Key Points: 
  • SOUTHFIELD, Mich., Oct. 14, 2021 /PRNewswire/ -- Helping Hand for Relief and Development (HHRD) observes this year's World Sight Day theme of Love Your Eyes with a nationwide Prevention of Blindness campaign advocating for cataract awareness and surgery.
  • A majority of its regions across the USA are running end of the year campaigns encouraging donors to give the gift of sight.
  • An estimated 2.2 billion people have near or distant vision impairment with almost half of these cases being preventable or yet to be addressed.
  • It is reported that nearly 100 million people suffer from cataracts, the leading cause of blindness.

Majority of Women Unaware That Heart Disease and Other Serious Health Issues Can Be Linked to Menopause

Thursday, October 14, 2021 - 3:18pm

Nearly 50 million women in the United States are entering menopause with a lack of relief, education, and support.

Key Points: 
  • Nearly 50 million women in the United States are entering menopause with a lack of relief, education, and support.
  • The decisions that a woman makes, or fails to make, at this point in her life can directly influence her future physical and mental health.
  • Treatment for diseases such as breast cancer can cause early onset menopause or menopause-like symptoms for many women.
  • Womaness products, which are available at Target, address three of the biggest perimenopause and menopause concerns: skincare, sexual health, and sleep.

Cleanlogic continues to Champion Blind and Visually Impaired through Blind Awareness Month

Thursday, October 14, 2021 - 2:00pm

An organization that empowers blind and visually impaired children with programs designed to provide them with the support and tools they need for future success.

Key Points: 
  • An organization that empowers blind and visually impaired children with programs designed to provide them with the support and tools they need for future success.
  • "We've always dedicated ourselves to raising awareness and developing programs to help this overlooked community and Blind Awareness Month is no different.
  • With these initiatives, Cleanlogic is determined to continue to drive awareness for Blindness Awareness Month, while helping blind and visually impaired individuals lead more independent lives.
  • Serving people who are blind or vision impaired since 1933, the San Antonio Lighthouse for the Blind & Vision Impaired provides rehabilitation services as well as employment for the blind and vision impaired in its light manufacturing assembly plant.

LensCrafters Partners with Australian Artist and Illustrator Karan Singh for the Your Eyes First Campaign in Support of World Sight Day

Thursday, October 14, 2021 - 2:00pm

Your Eyes Firstwill spotlight the ongoing theme of providing eye care to communities around the world and the services that LensCrafters offers to support this including a comprehensive eye exam and prescription glasses.

Key Points: 
  • Your Eyes Firstwill spotlight the ongoing theme of providing eye care to communities around the world and the services that LensCrafters offers to support this including a comprehensive eye exam and prescription glasses.
  • The campaign will showcase the company's commitment to providing clear sight care to those who need it most and their customers.
  • According to Singh, "The overarching message of "Your Eyes First" is what drew me to taking on this project.
  • "Withour collaboration withKaran Singh, we have the capability to highlight ourvision careefforts ina very creative way," said Alfonso Cerullo, General Manager, LensCrafters.

Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care

Thursday, October 14, 2021 - 2:00pm

Alcon is committed to educating people around the world about the importance of regular eye care as well as directly supporting access to eye care through the Alcon Foundation and Alcon Cares, in order to help people see brilliantly.

Key Points: 
  • Alcon is committed to educating people around the world about the importance of regular eye care as well as directly supporting access to eye care through the Alcon Foundation and Alcon Cares, in order to help people see brilliantly.
  • *1
    Beyond World Sight Day, Alcon helps people around the world see brilliantly through its corporate giving efforts, such as the Alcon Foundation and Alcon Cares programs.
  • Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
  • For more than 50 years, Alcon has partnered with non-profit organizations that help advance eye health, skills transfer, education and access to quality eye care around the world.

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

Thursday, October 14, 2021 - 1:00pm

WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases underserved by today's therapies, announced today the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA). The Company is seeking authorization to initiate a Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for the treatment of thyroid eye disease (TED), a debilitating disease that can cause proptosis (bulging eyes), double vision, and potential blindness.

Key Points: 
  • Our IND filing is an important milestone as we continue to advance the development of VRDN-001 as a potential treatment for patients suffering from Thyroid Eye Disease.
  • We look forward to launching this trial upon IND activation, stated Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian.
  • Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

NWEA Announces New Effort Using AI to Identify and Remove Barriers Within Math Assessments for Students with Visual Disabilities

Thursday, October 14, 2021 - 10:00am

For students, math instruction and assessment, especially online, can pose additional access barriers.

Key Points: 
  • For students, math instruction and assessment, especially online, can pose additional access barriers.
  • The AI for Accessibility grant-funded project will use math assessment data from students with visual disabilities and AI data analysis to identify patterns in online math test questions that can create barriers or support successes.
  • With thesedata, NWEA will then create prototype math questions that address the barriers within the design of the questions that showed to be most challenging to students with visual disabilities.
  • "For math students with visual disabilities, completing an online quiz to prove their aptitude can be impossible if the assessment doesn't present questions that are accessible.

Orbis: Nearly 3 in 5 not had routine eye test in past year with Gen X & Baby Boomers most at risk of vision loss

Thursday, October 14, 2021 - 8:00am

The findings are particularly worrying for Gen x and Baby Boomers who are more at risk of vision loss from preventable conditions.

Key Points: 
  • The findings are particularly worrying for Gen x and Baby Boomers who are more at risk of vision loss from preventable conditions.
  • This puts them at greater risk of avoidable vision loss from conditions such as cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration.
  • The YouGov poll of 2,025 people across Britain was commissioned by Orbis UK, the international eye health charity fighting avoidable blindness worldwide.
  • Globally 1.1 billion people live with vision loss and 9 in 10 of them live in low-to- middle-income countries, where Orbis works.